Tumor immune evasion mechanisms could be reversed by activating intracellular antiviral immune responses. It has been reported that the use of DNA methyltransferase (DNMT) inhibitors combined with ...

Two enzyme inhibitors join forces in reducing bladder cancer cell proliferation. n 1996, molecular biologist Kun Ping Lu, a ...

These findings provide the first evidence for the physiological function of TRAIL as a tumor suppressor ... responsible for the IFN-γ dependent pathway of NK-cell–mediated anti-tumor immunity.

The ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge CB2 0AH, U.K.

Malfunction of the p53 pathway is an almost universal hallmark of human tumours. [1,2] Somatic mutation of TP53 that results in the absence or dysfunction of p53 is one of the most common ...

Most often, an accumulation of mutations in both oncogenes and tumor-suppressor genes is responsible for the development of cancer. Oncogenes arise when normal genes present in the body ...

It is administered orally as a capsule. It is a new molecular entity (NME) with a structure based on a coumarin skeleton. The drug candidate acts by targeting B-Raf kinase, C-Raf kinase, mitogen ...

"Or it can be even more complex with say a large network of pathways within the tumor microenvironment all working to suppress the body's immune response," said Chen, who is also a researcher with ...

In other words, "the cannabinoid receptors were seen to be activated and the acetylcholine ... the clinical study of this new therapeutic pathway. To this end, they are working in collaboration ...

UHRF1 acts as a guide that recruits another protein to add methyl groups to the DNA of tumor suppressor genes. If researchers are able to intercept that guide, they might prevent or even undo ...

that many tumor cells have. When activated, DR5 can trigger the death of these cells by a self-destruct process called apoptosis. Researchers have been trying for more than 20 years to develop ...

GOVERNOR MAURA HEALEY RECENTLY SIGNED IT INTO LAW AS THE PHYSICIAN PATHWAY ACT. A BUSY PRIMARY CARE DOCTOR TAKES CARE OF 1500 TO UP TO 2000 PATIENTS, SO JUST EVEN ONE PERSON GO INTO A COMMUNITY ...